Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
MINNEAPOLIS, May 04, 2020 -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the.
Q4 2019 Tactile Systems Technology Inc Earnings Call
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -250.00% and 0.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, announced today that the Company’s motion to dismiss the qui tam complaint filed against the Company has been denied by the court. “We are disappointed that our motion to dismiss was denied and we will continue to defend ourselves against these allegations as the litigation moves forward,” said Gerald R. Mattys, Chief Executive Officer of Tactile Medical.
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Wednesday, February 26. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13698949. Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that first quarter of fiscal year 2020 financial results will be released after the market closes on Monday, May 4. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13701440. Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
Tactile Systems Technology (TCMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
To the annoyance of some shareholders, Tactile Systems Technology (NASDAQ:TCMD) shares are down a considerable 47% in...
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -4.35% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced the publication of a new clinical study demonstrating the prevalence of chronic venous insufficiency-related lymphedema (“CVI-related lymphedema,” also known as “Phlebolymphedema”). While cancer-related lymphedema remains a significant causal factor, the results of the study provide further support for the view espoused by some experts and accumulating evidence that phlebolymphedema, not cancer, may be the leading cause of lower extremity lymphedema in the U.S. today.
Tactile Systems Technology (TCMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today reported preliminary revenue results for the first quarter ended March 31, 2020, withdrew its 2020 financial outlook and provided a business update on the Company’s response to the COVID-19 pandemic. First quarter 2020 preliminary total revenue is expected to be in the range of $43.0 million to $44.0 million, representing growth of approximately 14% to 17% year-over-year. First quarter 2020 total revenue was negatively impacted by the COVID-19 pandemic beginning in the month of March.
Med-tech stock Tactile Systems (TCMD) has reported preliminary revenue results for the first quarter and withdrawn its 2020 financial outlook. The company, which focuses on developing medical devices for the at-home treatment of chronic diseases, also provided a business update on the company’s response to the Covid-19 pandemic.Specifically, TCMD pre-released first quarter revenue of $43–44 million, up 14–17% year-over-year, vs the consensus $44 million estimate. This includes Flexitouch system revenue in the range of $38 million to $39 million, representing growth of approximately 11% to 14% year-over-year.“Beginning in March, our revenue growth was impacted by the COVID-19 pandemic, which disrupted our ability to access our clinician customers and their patients. Specifically, we saw healthcare facilities and clinics restricting access to their clinicians, reducing patient consultations and treatments, or closing temporarily due to COVID-19” commented CEO Gerald Mattys.He continued: “As a direct result, we have changed many of our processes and practices… [so that we can] safely make our at-home therapies available for patients.”Mattys expects COVID-19 will continue to impact near-term financial but concludes “we remain confident in our long-term opportunity related to the $5+ billion U.S. lymphedema market and plan to continue expanding our commercial organization this year to further enhance our growth profile.”Overall, analysts are retaining a bullish position on the stock, with a Strong Buy consensus. In the last three months TCMD has received three buy ratings vs 1 hold rating, while the average analyst price target works out at $73 (88% upside potential). (See Tactile System’s stock analysis on TipRanks)However lone bear Suraj Kalia of Oppenheimer is highly critical of the stock, telling investors on April 6: “Ultimately, our view on Tactile remains, 1) Poor science: 2) No rigorous trials done; 3) Aggressive marketing driving the message; 4) Growth expectations unrealistic.”Related News: Streaming Pioneer Roku Launches UK Channel, Shares Soar 10% Global Payments Lowers Q1 Expectations, Removes Full Year Guidance GlaxoSmithKline, Vir Biotech Team Up in Hunt For Coronavirus Treatment More recent articles from Smarter Analyst: * Adaptive Biotechnologies’ Collaborations Could Be Vital in Fight Against COVID-19 * Could XBiotech’s Convalescent Plasma Program Make a Breakthrough in Treating COVID-19 Patients? * Got Guts? Get Tesla Stock at This High Valuation; This 5-Star Analyst Remains Sidelined * 3 Stocks Insiders Are Snapping Up
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
MINNEAPOLIS, Feb. 26, 2020 -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the.
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, announced today that the date, time and format of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) has changed and will now be held at 2:00 p.m. Central Time on Monday, May 4, 2020 by means of a virtual meeting. Due to the public health impact of the coronavirus (COVID-19) pandemic, and to support the health and safety of its stockholders, team members and other meeting participants, Tactile Medical has changed the date, time and format of its Annual Meeting. The Annual Meeting will now be held on Monday, May 4, 2020, at 2:00 p.m. Central Time, by means of a virtual meeting format only instead of the date, time and location previously disclosed in Tactile Medical’s proxy materials filed with the Securities and Exchange Commission on March 19, 2020.
TCMD earnings call for the period ending March 31, 2020.
Shares of Tactile Systems Tech (NASDAQ:TCMD) were unchanged at $48.72 after the company reported Q1 results.Quarterly Results Earnings per share were down 187.50% over the past year to ($0.07), which missed the estimate of ($0.02).Revenue of $43,675,000 higher by 16.10% year over year, which beat the estimate of $43,580,000.Looking Ahead Tactile Systems Tech hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 04, 2020View more earnings on TCMDTime: 12:04 PM ETWebcast URL: https://edge.media-server.com/mmc/p/cma8rsdcPrice Action 52-week high: $71.6552-week low: $29.47Price action over last quarter: down 7.55%Company Description Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.See more from Benzinga * Starwood Property Trust: Q1 Earnings Insights * CSI Compressco: Q1 Earnings Insights * Recap: Performance Food Group Q3 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Tactile Systems Technology, Inc. (“Tactile Medical”) (TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that Daniel L. Reuvers has been appointed President and Chief Executive Officer, effective June 8, 2020, to succeed Gerald R. Mattys who is retiring, as previously disclosed. Mr. Reuvers will also join the Board of Directors, effective June 8, 2020, filling a seat created by Mr. Mattys’ retirement from the Board, effective that same day. Mr. Mattys will serve as a consultant to the Company until June 2021 to ensure a seamless transition.